Most-Downgraded StocksMost-DowngradedNASDAQ:RAIN Rain Oncology (RAIN) Stock Forecast, Price & News $1.12 +0.01 (+0.95%) (As of 03:46 PM ET) Add Compare Share Share Today's Range$1.04▼$1.1550-Day Range$1.09▼$9.9352-Week Range$0.94▼$14.48Volume1.05 million shsAverage Volume798,004 shsMarket Capitalization$40.74 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Rain Oncology MarketRank™ ForecastAnalyst RatingHold2.42 Rating ScoreUpside/Downside1,445.5% Upside$17.00 Price TargetShort InterestHealthy6.20% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.36Based on 20 Articles This WeekInsider TradingSelling Shares$1.24 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.92) to ($1.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.62 out of 5 starsMedical Sector197th out of 1,980 stocksPharmaceutical Preparations Industry77th out of 978 stocks 4.2 Analyst's Opinion Consensus RatingRain Oncology has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 4 buy ratings, 9 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Rain Oncology has a forecasted upside of 1,445.5% from its current price of $1.10.Amount of Analyst CoverageRain Oncology has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.20% of the float of Rain Oncology has been sold short.Short Interest Ratio / Days to CoverRain Oncology has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rain Oncology has recently decreased by 1.75%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRain Oncology does not currently pay a dividend.Dividend GrowthRain Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RAIN. Previous Next 1.5 News and Social Media Coverage News SentimentRain Oncology has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Rain Oncology this week, compared to 4 articles on an average week.Search Interest32 people have searched for RAIN on MarketBeat in the last 30 days. This is an increase of 256% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Rain Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rain Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,243,750.00 in company stock.Percentage Held by Insiders21.90% of the stock of Rain Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.91% of the stock of Rain Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Rain Oncology are expected to grow in the coming year, from ($1.92) to ($1.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rain Oncology is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rain Oncology is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRain Oncology has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Rain Oncology (NASDAQ:RAIN) StockRain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.Read More Receive RAIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address RAIN Stock News HeadlinesJune 1, 2023 | seekingalpha.comRain Oncology slips on corporate and portfolio restructuringJune 1, 2023 | americanbankingnews.comBrokers Offer Predictions for Rain Oncology Inc.'s Q2 2023 Earnings (NASDAQ:RAIN)June 1, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 31, 2023 | americanbankingnews.comRain Oncology (NASDAQ:RAIN) Cut to Neutral at Roth CapitalMay 30, 2023 | msn.comEF Hutton Maintains Rain Oncology (RAIN) Hold RecommendationMay 30, 2023 | msn.comRoth MKM Downgrades Rain Oncology (RAIN)May 30, 2023 | bizjournals.comRain Oncology to cut 65% of jobs after cancer trial failureMay 30, 2023 | finanznachrichten.deRain Oncology Inc.: Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical ProgramsJune 1, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 30, 2023 | marketwatch.comRain Oncology to Cut 65% of Jobs in Cost-Cutting PushMay 30, 2023 | finance.yahoo.comRain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical ProgramsMay 28, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rain Oncology Inc. - RAINMay 27, 2023 | americanbankingnews.comRain Oncology Inc. to Post Q2 2023 Earnings of ($0.51) Per Share, SVB Leerink Forecasts (NASDAQ:RAIN)May 27, 2023 | americanbankingnews.comHC Wainwright Research Analysts Boost Earnings Estimates for Rain Oncology Inc. (NASDAQ:RAIN)May 25, 2023 | msn.comCitigroup Downgrades Rain Oncology (RAIN)May 25, 2023 | americanbankingnews.comRain Oncology (NASDAQ:RAIN) Downgraded by Citigroup to "Neutral"May 24, 2023 | americanbankingnews.comRain Oncology (NASDAQ:RAIN) Stock Rating Lowered by SVB LeerinkMay 24, 2023 | americanbankingnews.comRain Oncology (NASDAQ:RAIN) Rating Lowered to Market Perform at SVB LeerinkMay 24, 2023 | americanbankingnews.comRain Oncology (NASDAQ:RAIN) Rating Lowered to Market Perform at Lifesci CapitalMay 24, 2023 | americanbankingnews.comRain Oncology (NASDAQ:RAIN) Cut to "Neutral" at Piper SandlerMay 24, 2023 | americanbankingnews.comRain Oncology (NASDAQ:RAIN) Stock Rating Lowered by OppenheimerMay 24, 2023 | americanbankingnews.comRain Oncology (NASDAQ:RAIN) Rating Lowered to Neutral at GuggenheimMay 23, 2023 | msn.comJonesTrading Downgrades Rain Oncology (RAIN)May 23, 2023 | markets.businessinsider.comRain Oncology's Phase 3 Data Casts Doubt On Other Trials: Analyst Reevaluate Their ViewsMay 23, 2023 | americanbankingnews.comHC Wainwright Downgrades Rain Oncology (NASDAQ:RAIN) to NeutralMay 22, 2023 | markets.businessinsider.comMizuho Securities Keeps Their Buy Rating on Rain Therapeutics (RAIN)May 22, 2023 | bizjournals.comEast Bay cancer drug maker's stock plummets on late-stage trial resultsSee More Headlines RAIN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RAIN Company Calendar Last Earnings5/11/2023Today6/01/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RAIN CUSIPN/A CIK1724979 Webwww.rainthera.com Phone510-953-5559FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.00 High Stock Price Forecast$24.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+1,411.1%Consensus RatingHold Rating Score (0-4)2.42 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,720,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.40% Return on Assets-69.34% Debt Debt-to-Equity RatioN/A Current Ratio5.80 Quick Ratio5.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.60 per share Price / Book0.43Miscellaneous Outstanding Shares36,360,000Free Float28,400,000Market Cap$40.91 million OptionableNot Optionable Beta0.04 Key ExecutivesMr. Avanish Vellanki M.B.A. (Age 47)Co-Founder, CEO & Chairman Comp: $817.59kDr. Robert C. Doebele M.D. (Age 50)Ph.D., Co-Founder, Member of Scientific Advisory Board, Pres & Chief Scientific Officer Comp: $619.14kDr. Richard P. Bryce (Age 65)Exec. VP & Chief Medical Officer Comp: $496.25kMr. Nelson D. Cabatuan (Age 44)Sr. VP of Fin. & Admin. Ms. Theresa O'Connell M.S.Director of Corp. Devel. & OperationsMs. Vijaya Tirunagaru Ph.D.Sr. VP & Head of ResearchMr. Lucio Tozzi (Age 58)Sr. VP of Clinical Operations Ms. Buenaflor Nicolas M.P.H.VP, Head Global Drug Safety & PharmacovigilanceDr. Nora Ku M.D.MD & VP of Clinical Devel.Dr. Mehdi Paborji Ph.D. (Age 67)Sr. VP of Technical Operations More ExecutivesKey CompetitorsEledon PharmaceuticalsNASDAQ:ELDNBeyondSpringNASDAQ:BYSIFSD PharmaNASDAQ:HUGESynlogicNASDAQ:SYBXVincerx PharmaNASDAQ:VINCView All CompetitorsInsiders & InstitutionsBoxer Capital, LlcSold 995,000 sharesTotal: $1.24 M ($1.25/share)Alyeska Investment Group L.P.Bought 75,000 shares on 5/16/2023Ownership: 0.550%Geode Capital Management LLCBought 62,033 shares on 5/16/2023Ownership: 0.445%State Street CorpBought 24,100 shares on 5/16/2023Ownership: 0.151%Jane Street Group LLCBought 21,946 shares on 5/16/2023Ownership: 0.105%View All Insider TransactionsView All Institutional Transactions RAIN Stock - Frequently Asked Questions Should I buy or sell Rain Oncology stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rain Oncology in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RAIN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAIN, but not buy additional shares or sell existing shares. View RAIN analyst ratings or view top-rated stocks. What is Rain Oncology's stock price forecast for 2023? 13 analysts have issued 12-month price targets for Rain Oncology's shares. Their RAIN share price forecasts range from $11.00 to $24.00. On average, they expect the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 1,411.1% from the stock's current price. View analysts price targets for RAIN or view top-rated stocks among Wall Street analysts. How have RAIN shares performed in 2023? Rain Oncology's stock was trading at $8.00 at the beginning of the year. Since then, RAIN shares have decreased by 85.9% and is now trading at $1.1250. View the best growth stocks for 2023 here. When is Rain Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our RAIN earnings forecast. How were Rain Oncology's earnings last quarter? Rain Oncology Inc. (NASDAQ:RAIN) released its earnings results on Thursday, May, 11th. The company reported ($0.56) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.01. What ETF holds Rain Oncology's stock ? Horizon Kinetics Medical ETF holds 25,000 shares of RAIN stock, representing 0.97% of its portfolio. When did Rain Oncology IPO? (RAIN) raised $126 million in an initial public offering on Friday, April 23rd 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities acted as the underwriters for the IPO. What is Rain Oncology's stock symbol? Rain Oncology trades on the NASDAQ under the ticker symbol "RAIN." Who are Rain Oncology's major shareholders? Rain Oncology's stock is owned by many different institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (4.53%), GMT Capital Corp (2.27%), Sectoral Asset Management Inc. (1.33%), FMR LLC (0.96%), Ghost Tree Capital LLC (0.69%) and Alyeska Investment Group L.P. (0.55%). Insiders that own company stock include Aaron I Davis, Boxer Capital, Llc, Bvf Partners L P/Il, Cormorant Asset Management, Lp, Franklin M Berger, Perceptive Advisors Llc and Value Fund L P Biotechnology. View institutional ownership trends. How do I buy shares of Rain Oncology? Shares of RAIN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Rain Oncology's stock price today? One share of RAIN stock can currently be purchased for approximately $1.13. How much money does Rain Oncology make? Rain Oncology (NASDAQ:RAIN) has a market capitalization of $40.91 million. The company earns $-75,720,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. How can I contact Rain Oncology? The official website for the company is www.rainthera.com. The company can be reached via phone at 510-953-5559 or via email at bob@lifesciadvisors.com. This page (NASDAQ:RAIN) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rain Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.